Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of 35.31% is 271% above its 5-year average of -20.68%, near the high end of its 5-year range (-36.20%–35.31%).
350.25% above its 12-month average of -14.11%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -0.15%.
RETURN ON ASSETS (ROA)
35.31%
RETURN ON ASSETS (ROA) AVG TTM
-14.11%
RETURN ON ASSETS (ROA) AVG 3Y
-23.46%
RETURN ON ASSETS (ROA) AVG 5Y
-20.68%
RETURN ON ASSETS (ROA) AVG 10Y
-27.43%
RETURN ON ASSETS (ROA) AVG 15Y
-33.04%
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
+350.25%
CURRENT VS 3Y AVG
+250.51%
CURRENT VS 5Y AVG
+270.70%
CURRENT VS 10Y AVG
+228.73%
CURRENT VS 15Y AVG
+206.86%
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-31.48%
median of 786 covered companies
CURRENT VS SECTOR MEDIAN
+212.18%
vs the sector median at left
Fortress Biotech, Inc.
Market Cap
$67.93M
Return on Assets (ROA)
35.31%
TTM Avg
-14.11%
3Y Avg
-23.46%
5Y Avg
-20.68%
Market Cap
$67.84M
Return on Assets (ROA)
-33.34%
TTM Avg
-56.30%
3Y Avg
-89.26%
5Y Avg
-70.59%
Market Cap
$69.07M
Return on Assets (ROA)
-99.89%
TTM Avg
-66.19%
3Y Avg
-52.51%
5Y Avg
-39.81%
Market Cap
$69.48M
Return on Assets (ROA)
13.99%
TTM Avg
-24.80%
3Y Avg
-18.57%
5Y Avg
-29.63%
Market Cap
$65.85M
Return on Assets (ROA)
-33.77%
TTM Avg
-24.84%
3Y Avg
-18.48%
5Y Avg
-13.90%
Market Cap
$70.30M
Return on Assets (ROA)
-3.41%
TTM Avg
5.09%
3Y Avg
-8.30%
5Y Avg
-5.06%
Market Cap
$65.15M
Return on Assets (ROA)
-5.05%
TTM Avg
-7.03%
3Y Avg
-4.31%
5Y Avg
-4.67%
Market Cap
$65.08M
Return on Assets (ROA)
-162.91%
TTM Avg
-58.42%
3Y Avg
-64.67%
5Y Avg
-61.98%
Market Cap
$65.06M
Return on Assets (ROA)
-87.09%
TTM Avg
-130.17%
3Y Avg
-272.35%
5Y Avg
-217.34%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Fortress Biotech, Inc. (FBIO) | $67.93M | 35.31% | -14.11% | -23.46% | -20.68% |
| iBio, Inc. (IBIO)vs › | $67.84M | -33.34% | -56.30% | -89.26% | -70.59% |
| MindWalk Holdings Corp. (HYFT)vs › | $69.07M | -99.89% | -66.19% | -52.51% | -39.81% |
| Spero Therapeutics, Inc. (SPRO)vs › | $69.48M | 13.99% | -24.80% | -18.57% | -29.63% |
| XBiotech Inc. (XBIT)vs › | $65.85M | -33.77% | -24.84% | -18.48% | -13.90% |
| Champions Oncology, Inc. (CSBR)vs › | $70.30M | -3.41% | 5.09% | -8.30% | -5.06% |
| InterCure Ltd. (INCR)vs › | $65.15M | -5.05% | -7.03% | -4.31% | -4.67% |
| Gossamer Bio, Inc. (GOSS)vs › | $65.08M | -162.91% | -58.42% | -64.67% | -61.98% |
| Cingulate Inc. (CING)vs › | $65.06M | -87.09% | -130.17% | -272.35% | -217.34% |
| Heron Therapeutics, Inc. (HRTX)vs › | $64.75M | -13.50% | -6.86% | -33.98% | -45.40% |
ROA
35.3%
ROE
68.1%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | 3.67% |
| 2024-12-31 | -31.89% |
| 2023-12-31 | -36.20% |
| 2022-12-31 | -29.42% |
| 2021-12-31 | -16.32% |
| 2020-12-31 | -13.95% |
| 2019-12-31 | -17.65% |
| 2018-12-31 | -59.68% |
| 2017-12-31 | -27.19% |
| 2016-12-31 | -32.27% |
| 2015-12-31 | -40.83% |
| 2014-12-31 | -22.82% |
| 2013-12-31 | -36.94% |
| 2012-12-31 | -67.35% |
| 2011-12-31 | -155.55% |
| 2010-12-31 | -66.82% |
| 2009-12-31 | -217.31% |
| 2008-12-31 | 0.00% |
